中国生物技术公司引领了PD-L1/VEGF双抗药物的研发。BMS将与BioNTech共同开发并商业化用于治疗多种实体瘤的下一代肿瘤免疫疗法，其中的核心资 产源自中国公司。 德国生物技术公司BioNTech去年花了不到10亿美元收购中国公司获得的在研肿瘤药，仅半年时间，被转手卖了超过110亿美元。 当地时间6月2日，在美国临床肿瘤学会（ASCO）年会上，百时美施贵宝（BMS）宣布拟斥资高达111亿美元与BioNTech合作，以获得该公司正在开发的下 一代癌症免疫疗法，其中的核心资产源自中国公司。 据两家公司的公开声明，BMS将与BioNTech共同开发并商业化一款肿瘤药物BNT327，这是一种靶向PD-L1和VEGF-A的双特异性抗体药物，用于治疗多种 实体瘤。 BNT327是BioNTech去年通过收购中国生物技术公司普米斯生物获得。去年11月，BioNTech仅以8亿美元就收购了普米斯生物，加上后续1.5亿美元里程碑付 款，整个收购交易不到10亿美元。BioNTech由此获得了BNT327全球的全部权益。 目前，BNT327正在作为广泛期小细胞肺癌和非小细胞肺癌的一线治疗方案进行临床试验。迄今为止，已有超过 ...

Group 1 - The research achievements of Chinese innovative pharmaceutical companies are increasingly attracting the attention of multinational pharmaceutical giants, with approximately 31% of innovative drug candidates introduced by large multinational companies in 2024 coming from China, compared to zero in 2019 [1][3] - At the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, over 70 studies from Chinese innovative pharmaceutical companies were selected for oral presentations, with a focus on bispecific antibodies and ADC drug research [1] - Kangfang Biopharma and its partner Summit Therapeutics released the first global Phase 3 clinical trial results for the PD-1/VEGF bispecific antibody ivonescimab, showing a 48% reduction in the risk of disease progression or death for previously treated patients with EGFR-mutant non-squamous non-small cell lung cancer (NSCLC) [1] Group 2 - IBI363, a globally innovative PD-1/IL-2α-bias bispecific fusion protein developed by Innovent Biologics, showed clinical data for treating immune-treated advanced melanoma at ASCO, along with a comparison study against Merck's Keytruda [2] - Kelun-Biotech presented six clinical research results at ASCO, including the ADC drug sac-TMT for previously treated advanced EGFR-mutant non-small cell lung cancer patients [2] - In the previous month, Zai Lab announced that the FDA granted fast track designation for its potential ADC drug ZL-1310 for the treatment of extensive-stage small cell lung cancer (ES-SCLC), with updates expected at ASCO [2] Group 3 - I-Mab presented preliminary results of its ADC drug DB-1310 for treating advanced solid tumors at ASCO, focusing on safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity [3]